Effect of polyethylene glycol loxenatide on weight loss in super-obese patients with type 2 diabetes: a randomized controlled trial - PubMed
5 days ago
- #weight loss
- #type 2 diabetes
- #PEG-Loxe
- Polyethylene glycol loxenatide (PEG-Loxe) was studied for weight loss in super-obese patients with type 2 diabetes.
- The study was a randomized controlled trial with 123 participants divided into low-dose (300 μg/week), high-dose (400 μg/week), and placebo groups.
- Weight reduction was significantly greater in both PEG-Loxe groups compared to placebo after 24 weeks.
- Glycated hemoglobin levels decreased more in the PEG-Loxe groups than in the placebo group.
- PEG-Loxe treatment also reduced waist circumference and increased HDL levels.
- Adverse reactions, mainly gastrointestinal, were more common in the PEG-Loxe groups.
- The study concluded that PEG-Loxe is effective for weight loss and glycemic control in super-obese T2DM patients.